Sugi Predict

Sugi Predict / Compounds / SCHEMBL3661837

SCHEMBL3661837

SCHEMBL3661837

COc1cc(O)c(C(C)=O)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 1.00
▸ HMGCR P04035 2/20 0.63
▸ CYP3A4 P08684 6/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ HPGD P15428 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 2/20 0.50
▸ USP2 O75604 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ RECQL P46063 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ FYN P06241 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398255 1.00 HTT (1.00) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL14780513 0.89 HTT (0.81) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL31175997 0.89 HTT (0.81) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL1545430 0.89 HTT (0.81) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL30217452 0.86 HTT (0.74) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL14566480 0.86 HTT (0.75) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL1493973 0.84 HTT (0.72) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL6329490 0.84 HTT (0.72) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL3645035 0.84 HTT (0.72) HTTHMGCRCYP3A4MAPK1HPGD
SCHEMBL1494029 0.84 HTT (0.72) HTTHMGCRCYP3A4MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114146071-B Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2023-02-28 — — CN claimed
CN-114146071-A Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2022-03-08 — — CN claimed
EP-4678637-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS A-chembio Co., Ltd (KR) 2026-01-14 — — EP disclosed
CN-119775247-A Transient receptor potential cation channel TRPV3 inhibitor and application thereof 苏中药业集团股份有限公司 2025-04-08 — — CN disclosed
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS A-CHEMBIO CO., LTD (KR) 2024-09-12 — — US disclosed
WO-2024186175-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS 주식회사 에이켐바이오 2024-09-12 — — WO disclosed
WO-2023090908-A1 NOVEL FLAVONOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE 고려대학교 세종산학협력단 2023-05-25 — — WO disclosed
CN-114146071-B Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2023-02-28 — — CN disclosed
EP-3430000-B1 PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR AFFERENT PHARMACEUTICALS INC (US) 2022-12-28 — — EP disclosed
WO-2022255765-A1 NOVEL FLUORINE-SUBSTITUTED FLAVONOID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES, COMPRISING SAME 주식회사 에즈큐리스 2022-12-08 — — WO disclosed
CN-115040497-A Application of paeonol derivative in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2022-09-13 — — CN disclosed
EP-1548008-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-06-29 — — EP disclosed
WO-2004083199-A1 SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2004-09-30 — — WO disclosed
WO-2004083208-A1 SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2004-09-30 — — WO disclosed
WO-2004083209-A1 SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2004-09-30 — — WO disclosed
US-5808105-A 4-phenoxycoumarins as herbicidal agents AMERICAN CYANAMID COMPANY (US) 1998-09-15 — — US disclosed
US-5759959-A SELECTIVE CONTROL OF MONOCOTYLEDENOUS WEEDS IN THE PRESENCE OF A CROP PLANT AMERICAN CYANAMID COMPANY (US) 1998-06-02 — — US disclosed
US-5681968-A EFFECTIVE TO CONTROL GRASS AND OTHER MONOCOTOLYDENOUS WEEDS AMERICAN CYANAMID COMPANY (US) 1997-10-28 — — US disclosed
US-5563280-A CONTROLLING MONOCOTYLEDENOUS WEEDS IN CROPS AMERICAN CYANAMID CO. (US) 1996-10-08 — — US disclosed
EP-0694257-A1 4-Phenoxycoumarins and thio derivatives thereof, their preparation and use as herbicides AMERICAN CYANAMID COMPANY (US) 1996-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS HGF, FN1, SMAD2 HTT 2045/4885HMGCR 2468/4885CYP3A4 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.